TAK-700, also known as Orteronel or TAK700, is a nonsteroidal androgen synthesis inhibitor that has been developed as a potential treatment for prostate cancer. It is an orally active, small molecule inhibitor of the 17,20-lyase enzyme, which is responsible for the conversion of pregnenolone and progesterone into androgens, including testosterone.
Chemical name: (2S,4S)-4-(4-cyanophenyl)-2-((4-fluorophenyl)sulfonyl)-N-hydroxy-2-(1-methylpiperidin-4-yl)pyrrolidine-1-carboxamide Molecular formula: C24H28FN3O4S Formula weight: 475.57 g/mol CAS No: 426219-18-3
Top Ten Keywords from Google:
Synonyms: Orteronel, TAK700, 426219-18-3
Health benefits of this product:
TAK-700 is a potential treatment option for prostate cancer patients. Prostate cancer is one of the most common cancers in men worldwide, and it is typically treated with androgen deprivation therapy (ADT), which is designed to lower testosterone levels in the body. However, over time, some patients may develop resistance to ADT, and their tumors may continue to grow despite low testosterone levels. TAK-700 works by inhibiting the production of androgens, including testosterone, which can help slow or stop the growth of prostate cancer cells.
Potential effects:
The potential effects of TAK-700 include slowing or stopping the growth of prostate cancer cells, reducing the size of tumors, and potentially prolonging the survival of patients with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread beyond the prostate gland and no longer responds to hormone therapy alone.
Product mechanism:
TAK-700 works by inhibiting the 17,20-lyase enzyme, which is involved in the synthesis of androgen hormones such as testosterone. By blocking this enzyme, TAK-700 reduces the production of androgens, which can help slow or stop the growth of prostate cancer cells.
Safety:
Like all medications, TAK-700 can have side effects, and it should only be taken under the supervision of a healthcare professional. Some potential side effects of TAK-700 include fatigue, nausea, diarrhea, decreased appetite, and elevated liver enzymes. In clinical trials, some patients experienced more serious side effects, such as hypertension and cardiac events. As such, it is important for patients taking TAK-700 to have regular check-ups with their healthcare providers to monitor their overall health.
Side effects:
Common side effects of TAK-700 include fatigue, nausea, diarrhea, decreased appetite, and elevated liver enzymes. Some patients may also experience more serious side effects, such as hypertension and cardiac events. It is important for patients taking TAK-700 to report any side effects to their healthcare provider right away.
Dosing information:
The dosing of TAK-700 depends on a patient's individual medical history and condition. In clinical trials, TAK-700 was given once daily at doses ranging from 200 mg to 1200 mg, usually in combination with another medication, such as prednisone. Patients should always follow their healthcare provider's dosing instructions carefully and never exceed the recommended dose.
Conclusion:
TAK-700 is a promising new treatment option for patients with prostate cancer, particularly those who have developed resistance to standard hormone therapies. By inhibiting the production of androgens, including testosterone, TAK-700 can help slow or stop the growth of prostate cancer cells, potentially leading to improved outcomes for patients. However, like all medications, TAK-700 can have side effects, and it should only be taken under the supervision of a healthcare professional. Patients with prostate cancer should discuss all available treatment options with their healthcare provider to determine the best course of action for their individual case.
